Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Gender influences the class III and V β-tubulin ability to predict poor outcome in colorectal cancer.

Mariani M, Zannoni GF, Sioletic S, Sieber S, Martino C, Martinelli E, Coco C, Scambia G, Shahabi S, Ferlini C.

Clin Cancer Res. 2012 May 15;18(10):2964-75. doi: 10.1158/1078-0432.CCR-11-2318. Epub 2012 Mar 21.

2.

Expression of Tubb3, a beta-tubulin isotype, is regulated by androgens in mouse and rat Sertoli cells.

De Gendt K, Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, Wilkinson MF, Claessens F, Swinnen JV, Verhoeven G.

Biol Reprod. 2011 Nov;85(5):934-45. doi: 10.1095/biolreprod.110.090704. Epub 2011 Jul 6.

3.

High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.

Levallet G, Bergot E, Antoine M, Creveuil C, Santos AO, Beau-Faller M, de Fraipont F, Brambilla E, Levallet J, Morin F, Westeel V, Wislez M, Quoix E, Debieuvre D, Dubois F, Rouquette I, Pujol JL, Moro-Sibilot D, Camonis J, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique (IFCT)..

Mol Cancer Ther. 2012 May;11(5):1203-13. doi: 10.1158/1535-7163.MCT-11-0899. Epub 2012 Mar 12.

4.

RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.

Xu YC, Zhang FC, Li JJ, Dai JQ, Liu Q, Tang L, Ma Y, Xu Q, Lin XL, Fan HB, Wang HX.

Oncol Rep. 2015 Oct;34(4):1883-94. doi: 10.3892/or.2015.4183. Epub 2015 Aug 7.

PMID:
26252353
5.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P; LACE-Bio Group..

Ann Oncol. 2012 Jan;23(1):86-93. doi: 10.1093/annonc/mdr033. Epub 2011 Apr 6.

6.

A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.

Hara T, Ushio K, Nishiwaki M, Kouno J, Araki H, Hikichi Y, Hattori M, Imai Y, Yamaoka M.

Cell Biol Int. 2010 Jan 25;34(2):177-84. doi: 10.1042/CBI20090030.

PMID:
19947927
7.

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.

Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, Kondo H, Nakajima T, Yamamoto N.

Int J Clin Oncol. 2013 Jun;18(3):371-9. doi: 10.1007/s10147-012-0386-8. Epub 2012 Feb 23.

PMID:
22358390
8.

Predicting the outcome of chemotherapy for colorectal cancer.

Allen WL, Coyle VM, Johnston PG.

Curr Opin Pharmacol. 2006 Aug;6(4):332-6. Epub 2006 Jun 5. Review.

PMID:
16750422
9.

Decreased expression of class III β-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.

Shimizu A, Kaira K, Yasuda M, Asao T, Ishikawa O.

Melanoma Res. 2016 Feb;26(1):29-34. doi: 10.1097/CMR.0000000000000208.

PMID:
26426765
10.

Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial.

Vilmar AC, Santoni-Rugiu E, Sørensen JB.

Clin Cancer Res. 2011 Aug 1;17(15):5205-14. doi: 10.1158/1078-0432.CCR-11-0658. Epub 2011 Jun 20.

11.

Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.

Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Naito T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N.

J Thorac Oncol. 2011 Mar;6(3):606-13. doi: 10.1097/JTO.0b013e31820b9b35.

12.

Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.

Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T.

Int J Oncol. 2008 Jun;32(6):1227-35.

PMID:
18497984
13.

Class III β-tubulin (TUBB3): more than a biomarker in solid tumors?

Mariani M, Shahabi S, Sieber S, Scambia G, Ferlini C.

Curr Mol Med. 2011 Dec;11(9):726-31. Review.

PMID:
21999149
14.

Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.

Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, Scambia G, Ferlini C.

Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.

PMID:
24661907
15.

Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.

Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Jänne OA, Visakorpi T.

Cancer Res. 2009 Oct 15;69(20):8141-9. doi: 10.1158/0008-5472.CAN-09-0919. Epub 2009 Oct 6.

16.

Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.

Lee KM, Cao D, Itami A, Pour PM, Hruban RH, Maitra A, Ouellette MM.

Histopathology. 2007 Oct;51(4):539-46. Epub 2007 Aug 21.

PMID:
17714470
17.

Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.

Yu J, Gao J, Lu Z, Gong J, Li Y, Dong B, Li Z, Zhang X, Shen L.

Eur J Cancer. 2014 Sep;50(13):2328-35. doi: 10.1016/j.ejca.2014.06.017. Epub 2014 Jul 10.

PMID:
25016949
18.

Molecular mechanisms of patupilone resistance.

Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, Bartollino S, Gallo D, Scambia G, Ferlini C.

Cancer Res. 2008 Dec 15;68(24):10197-204. doi: 10.1158/0008-5472.CAN-08-2091.

19.

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.

Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.

Cancer Chemother Pharmacol. 2014 Oct;74(4):777-86. doi: 10.1007/s00280-014-2562-1. Epub 2014 Aug 9.

PMID:
25107571
20.

Differential CARM1 expression in prostate and colorectal cancers.

Kim YR, Lee BK, Park RY, Nguyen NT, Bae JA, Kwon DD, Jung C.

BMC Cancer. 2010 May 13;10:197. doi: 10.1186/1471-2407-10-197.

Supplemental Content

Support Center